CytoMed Therapeutics Limited

NasdaqCM GDTC

CytoMed Therapeutics Limited Goodwill for the year ending December 31, 2023: USD 355.00

CytoMed Therapeutics Limited Goodwill is USD 355.00 for the year ending December 31, 2023, a 34.62% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

CytoMed Therapeutics Limited Goodwill for the year ending December 31, 2022 was USD 263.71, a 0.46% change year over year.
CytoMed Therapeutics Limited Goodwill for the year ending December 31, 2021 was USD 262.50, a -2.12% change year over year.
CytoMed Therapeutics Limited Goodwill for the year ending December 31, 2020 was USD 268.18, a 2.56% change year over year.
CytoMed Therapeutics Limited Goodwill for the year ending December 31, 2019 was USD 261.48.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqCM: GDTC

CytoMed Therapeutics Limited

CEO	Mr. Chee Kong Choo
IPO Date	April 14, 2023
Location	Singapore
Headquarters	1 Commonwealth Lane, No. 08-22
Employees	28
Sector	Healthcare
Industries Biotechnology 3D Printing Robotics

Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Key trends

Past 5 years